Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908478 · ClinicalTrials.gov registry record · Phase 1
Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer
A Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01908478 is a Phase 1 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 34 participants.
The verdict
NCT01908478, a Phase 1 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a Phase I Study of veliparib (ABT-888) in combination with Gemcitabine and Intensity Modulated Radiation Therapy in Patients with Locally Advanced, Unresectable Pancreatic Cancer. Primary Objectives: * Determine the maximum tolerable dose of veliparib in combination with gemcitabine and intensity modulated radiation therapy in patients with locally advanced pancreatic cancer. * Determine the safety and toxicity of the combination of veliparib with gemcitabine and radiation therapy in patients with locally advanced pancreatic cancer
Interventions
- DRUG Gemcitabine
- DRUG Veliparib
- RADIATION Intensity modulated radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2013-10-02 |
| Est. Completion | 2020-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01908478
The ClinicalTrials.gov registry entry for NCT01908478 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT01908478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01908478 about?
NCT01908478 is a clinical study titled "Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer". This is a Phase I Study of veliparib (ABT-888) in combination with Gemcitabine and Intensity Modulated Radiation Therapy in Patients with Locally Advanced, Unresectable Pancreatic Cancer. Primary Objectives: * Determine the maximum tolerable dose of veliparib in combination with gemcitabine and in...
What is the current status of trial NCT01908478?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2013-10-02. Estimated completion is 2020-07-06.
What interventions are being tested in trial NCT01908478?
The interventions under investigation include: Gemcitabine (DRUG), Veliparib (DRUG), Intensity modulated radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01908478?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.